Connect with us

Hi, what are you looking for?

Jewish Business News

Business

Kadimastem Announces Positive Interim Results from Phase 2 in ALS

 

Kadimastem leadership and the cell product manufacturing process.

Israel-based Kadimastem, a biotechnology company developing cell therapies for the treatment of severe debilitating diseases announced positive interim results from the Phase 2 clinical trial.

The company’s lead product, AstroRx, showed a positive efficacy signal and a good safety profile in a clinical Cohort B Phase 1/2a in ALS.

The comparison between the ALSFRS-R change before and after treatment conveys a clinically meaningful decline of more than 50% in disease progression rate for a period of 3 months for both cohorts,” said Kadimastem CEO Rami Epstein.

Please help us out :
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at [email protected].
Thank you.

“The effect was even more profound in patients who deteriorate rapidly. Repeated administrations of the treatment, planned to be assessed in future clinical trials, will hopefully extend the duration of the beneficial effect. These results strengthen our commitment to bringing an innovative therapeutic treatment to ALS, a devastating disease currently having no effective treatment.”

“The positive interim results of Cohort A and B strongly support our next global clinical development stages, added Epstein. “We are now focused on advancing strategic FDA regulatory processes that will necessitate the conduct of global multi-center clinical trials. In support, the Company is also dedicating resources to production process scale-up as well as to the development of a 2nd generation of AstroRx as a frozen product that will accelerate our clinical development plan to support market authorization,” he said.

Newsletter



Advertisement

You May Also Like

World News

In the 15th Nov 2015 edition of Israel’s good news, the highlights include:   ·         A new Israeli treatment brings hope to relapsed leukemia...

Life-Style Health

Medint’s medical researchers provide data-driven insights to help patients make decisions; It is affordable- hundreds rather than thousands of dollars

Entertainment

The Movie The Professional is what made Natalie Portman a Lolita.

Travel

After two decades without a rating system in Israel, at the end of 2012 an international tender for hotel rating was published.  Invited to place bids...